Denmark-based in vitro diagnostics company BioPorto signed an agreement with Roche Holding to globally distribute its CE-marked neutrophil gelatinase-associated lipocalin test for use on Cobas c 502 and Cobas c 501 analyzers to diagnose acute kidney injury; terms were undisclosed. Clinical studies are being conducted by BioPorto as it expects to receive FDA approval for the test later this year.
BioPorto enters distribution deal with Roche for NGAL test
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.